VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.

(2015) Leonidas Platanias et al.   Oncotarget

Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide

(2012) D. J. Goussetis et al.   BLOOD

Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide-Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1

(2012) R. Wang et al.   CLINICAL CANCER RESEARCH

Angiogenesis: A Target in Solid Tumors, Also in Leukemia?

(2011) T. Schmidt et al.   Hematology-American Society of Hematology Education Program

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

(2009) Q.-Y. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of microRNA with antisense oligonucleotides

(2007) Christine C. Esau   METHODS